Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
It would be difficult to introduce a uniform pricing rule for medically essential but unprofitable drugs in the FY2016 NHI pricing reform to bail out all such products, Shuji Shirakawa, a key member of the Central Social Insurance Medical Council…
To read the full story
Related Article
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
- Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
- Gist of FY2014 NHI Price Revision
December 26, 2013
ORGANIZATION
- Keidanren Calls for English Drug Filings to Be Opened to Japan-Based Firms
September 16, 2026
- JPWA Disbands Kumamoto Quake Disaster Response HQ
September 14, 2026
- BMS Prods Japan to Better Reward Regenerative Medicine Innovation
September 11, 2026
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…